Keros Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 3, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	408	641	1,191	1,323	1,369	1,635
Market Cap Growth	-2.34%	-46.17%	-9.94%	-3.39%	-16.27%	-
Enterprise Value	-268	130	918	1,084	1,149	1,502
Last Close Price	13.40	15.83	39.76	48.02	58.51	70.54
PS Ratio	1.65	180.63	7888.64	-	68.11	-
PB Ratio	0.77	1.12	3.59	4.77	5.63	6.25
P/TBV Ratio	0.58	1.12	3.59	4.77	5.63	6.25
EV/Sales Ratio	-	36.57	6076.87	-	57.16	-
Debt / Equity Ratio	0.03	0.03	0.04	0.05	0.00	0.00
Debt / FCF Ratio	0.20	-	-	-	-	-
Net Debt / Equity Ratio	-0.96	-0.95	-0.95	-0.96	-0.94	-1.01
Net Debt / EBITDA Ratio	-14.11	2.58	1.87	2.33	4.09	5.71
Net Debt / FCF Ratio	-7.76	3.32	2.49	3.73	3.62	7.13
Asset Turnover	0.37	0.01	0	-	0.08	-
Quick Ratio	29.02	20.56	13.63	16.92	20.96	37.04
Current Ratio	29.86	21.45	14.25	17.27	21.23	37.27
Return on Equity (ROE)	10.42%	-41.46%	-50.19%	-40.22%	-23.27%	-34.60%
Return on Assets (ROA)	4.40%	-26.73%	-31.39%	-25.53%	-13.43%	-20.80%
Return on Capital Employed (ROCE)	6.50%	-35.80%	-49.20%	-39.60%	-23.20%	-17.80%
Earnings Yield	15.79%	-29.22%	-12.84%	-7.91%	-4.29%	-2.77%
FCF Yield	21.33%	-25.39%	-10.66%	-5.39%	-4.61%	-2.27%
Buyback Yield / Dilution	-17.52%	-27.13%	-16.66%	-8.17%	-50.48%	-566.41%

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q